Literature DB >> 172930

Human sleep during chronic morphine intoxication.

D C Kay.   

Abstract

The sleep of 6 opiate addicts was studied for 11 nights during 3 phases of a chronic morphine cycle. The control phase consisted of 5 consecutive nights before morphine administration. The induction phase consisted of 1 night at 21-36 days after the onset of morphine administration, when the daily dose was 140-220 mg. The stable dose phase consisted of 5 consecutive nights after the subjects had received 240 mg of morphine daily for 8-19 weeks. No sleep could be studied during the withdrawal phase. Sleep was continuously monitored with EEG, EMG and EOG. Chronic morphine produces signs of a small but persistent sleep disturbance: delta sleep (early night) becomes less stable and shifts toward later in the night, waking state increases during the middle of the night, RME sleep (expecially its activated EEG without eye movements) decreases, the RMES cycle increases, and burst of delta activity (with mean duration of 5-6 sec) increase. Although this disturbance persists throughout the night, it is much less than that seen after single doses of morphine in a previous study. With chronic morphine, therefore, partial tolerance develops to the sleep disturbance produced by morphine. The small but persistent nocturnal arousal during chronic morphine contrasts with the sedation seen during chronic methadone. Both opioids produce an increase in delta bursts during chronic administration, which might be an EEG phenomenon specific to chronic opioid intake.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 172930     DOI: 10.1007/bf00420997

Source DB:  PubMed          Journal:  Psychopharmacologia


  26 in total

1.  AMOUNT OF DREAMING: EFFECT OF INCENTIVE, ADAPTATION TO LABORATORY, AND INDIVIDUAL DIFFERENCES.

Authors:  A RECHTSCHAFFEN; P VERDONE
Journal:  Percept Mot Skills       Date:  1964-12

2.  Morphine effects on human REM state, waking state and NREM sleep.

Authors:  D C Kay; R B Eisenstein; D R Jasinski
Journal:  Psychopharmacologia       Date:  1969

3.  The orienting reflex during waking and sleeping.

Authors:  L C Johnson; A Lubin
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1967-01

4.  Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates.

Authors:  C A Haertzen; N T Hooks
Journal:  J Nerv Ment Dis       Date:  1969-06       Impact factor: 2.254

5.  Heroin and human sleep.

Authors:  S A Lewis; I Oswald; J I Evans; M O Akindele; S L Tompsett
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1970-04

6.  Methadone--a reevaluation.

Authors:  W R Martin; D R Jasinski; C A Haertzen; D C Kay; B E Jones; P A Mansky; R W Carpenter
Journal:  Arch Gen Psychiatry       Date:  1973-02

7.  The addiction cycle to narcotics in the rat and its relation to catecholamines.

Authors:  T Akera; T M Brody
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

8.  Autonomic correlates of the spontaneous K-complex.

Authors:  L C Johnson; W E Karpan
Journal:  Psychophysiology       Date:  1968-04       Impact factor: 4.016

9.  Generalized seizure discharges and possible precipitating mechanisms.

Authors:  E Niedermeyer
Journal:  Epilepsia       Date:  1966-03       Impact factor: 5.864

10.  Electroencephalographic, electromyographic and behavioral correlates during a cycle of selfmaintained morphine addiction in the rat.

Authors:  K Khazan; J R Weeks; L A Schroeder
Journal:  J Pharmacol Exp Ther       Date:  1967-03       Impact factor: 4.030

View more
  15 in total

1.  Effects of chronic treatment with methadone and naltrexone on sleep in addicts.

Authors:  J Staedt; F Wassmuth; G Stoppe; G Hajak; A Rodenbeck; W Poser; E Rüther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

2.  Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.

Authors:  Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Eric C Strain
Journal:  Addict Behav       Date:  2017-07-14       Impact factor: 3.913

3.  Sleep and GABA levels in the oral part of rat pontine reticular formation are decreased by local and systemic administration of morphine.

Authors:  C J Watson; R Lydic; H A Baghdoyan
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

4.  Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals.

Authors:  Andrea G Gillman; Joseph K Leffel; Ann E K Kosobud; William Timberlake
Journal:  Behav Brain Res       Date:  2009-07-10       Impact factor: 3.332

5.  Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.

Authors:  Jeremiah W Bertz; David H Epstein; David Reamer; William J Kowalczyk; Karran A Phillips; Ashley P Kennedy; Michelle L Jobes; Greg Ward; Barbara A Plitnick; Mariana G Figueiro; Mark S Rea; Kenzie L Preston
Journal:  J Subst Abuse Treat       Date:  2019-08-14

6.  The effects of various protein synthesis inhibitors on the sleep-wake cycle of rats.

Authors:  J A Rojas-Ramírez; E Aguilar-Jiménez; A Posadas-Andrews; J G Bernal-Pedraza; R R Drucker-Colín
Journal:  Psychopharmacology (Berl)       Date:  1977-07-18       Impact factor: 4.530

7.  Activity of murine raphe magnus cells predicts tachypnea and on-going nociceptive responsiveness.

Authors:  Kevin M Hellman; Thaddeus S Brink; Peggy Mason
Journal:  J Neurophysiol       Date:  2007-10-03       Impact factor: 2.714

8.  Morphine-like insomnia from heroin in nondependent human addicts.

Authors:  D C Kay; W B Pickworth; G L Neider
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

Review 9.  Sleep and alertness disturbance and substance use disorders: A bi-directional relation.

Authors:  Timothy Roehrs; Mohammad Sibai; Thomas Roth
Journal:  Pharmacol Biochem Behav       Date:  2021-02-12       Impact factor: 3.533

10.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.